Latest research on Fluticasone

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis.

Latest findings

When skin lesions continued to worsen, topical Fluticasone was attempted, yielding minimal relief. [source, 2016]
Ultimately, a combination of topical Fluticasone, Cyclosporine, Acitretin, oral Prednisone, and intramuscular methotrexate yielded mild to moderate improvement for periods of time. [source, 2016]
The administration of topical Fluticasone, Cyclosporine, and oral methotrexate were continued, under the presumed diagnosis of atopic dermatitis. [source, 2016]
Traditionally, a high dose of ICS (eg, Fluticasone dipropionate 500 µg bid) is prescribed; however, there is little high-quality information available on the dose−response relationship. [source, 2016]
A study of once-daily Fluticasone furoate, at a dosage of 50−100 µg daily in addition to vilanterol, demonstrated a progressive treatment benefit, with no apparent benefit above this dose. [source, 2016]
The annual incidence of moderate or severe exacerbations, systemic corticosteroid prescriptions, and hospitalizations were reduced significantly in the TORCH study with both the β2-agonist Salmeterol and corticosteroid Fluticasone. [source, 2016]
The TORCH study demonstrated this for the first time, comparing Fluticasone propionate (FP) and placebo [2, 3]. [source, 2016]
Also in a retrospective pooled analysis of 5 RCTs comparing Zafirlukast to Fluticasone as monotherapy, the effects of Zafirlukast appeared to be lost in older adults (aged ≥50 years) [72]. [source, 2016]
Compared with placebo, ICS such as Fluticasone propionate (FP) and Budesonide reduce exacerbations by up to 20% as monotherapy, and up to 30% in combination with a long-acting β2-agonist (LABA). [source, 2016]
A recent retrospective analysis of data from two parallel 1-year studies of once-daily ICS/LABA, Fluticasone furoate (FF)/vilanterol (VI) in patients with moderate-to-very severe COPD showed a greater reduction of moderate and severe exacerbations in patients with a blood eosinophil level ≥2% vs <2% when treated with FF/VI compared with VI alone.18 19 [source, 2016]